विवरण
🎥 Video Details 🎥
🌟 About This Video 🌟
The U.S. Food and Drug Administration classified a Teva Pharmaceuticals recall of about 300,133 clonidine transdermal patch cartons as Class II on April 13, 2026, citing an unapproved raw material and potential, reversible harm. The FDA recall covers Clonidine Transdermal System, USP in 0.1 mg/day, 0.2 mg/day, and 0.3 mg/day strengths distributed at retail under Teva’s label. Actavis Laboratories manufactured the recalled clonidine patches for Teva, with lot expirations from April 2026 through February 2027. A Class II recall involves temporary or reversible harm with low risk of serious effects. The California State Board of Pharmacy noted unknown safety; Teva found no meaningful risk. Abrupt discontinuation can cause dangerous blood pressure spikes; FDA MedWatch: 1-800-FDA-1088. #fdanotice #drugrecall #tevapharma #clonidinepatch #patientsafety
🤖 Crafted with Rizzle AI 🤖
This video was created using Rizzle AI, the ingenious no-edit video creation platform, with industry-leading assets from GettyImages and Soundstripe. Elevate your video content with Rizzle AI: https://app.rizzle.com/create
🔔 If you enjoyed this video, don't forget to like, share, and subscribe! 🔔